Alzheimer's disease (AD) is characterized by an imbalance between production and
clearance of amyloid-β (Aβ) species. Aβ peptides can transform structurally from monomers …

Oligomers which form during amyloid fibril assembly are considered to be key contributors
towards amyloid disease. However, understanding how such intermediates form, their …

Aducanumab, a human-derived antibody targeting amyloid-β (Aβ), is in Phase 3 clinical
trials for the treatment of Alzheimer's disease. Biochemical and structural analyses show that …

Protein misfolding and aggregation are characteristic of a wide range of neurodegenerative
disorders, including Alzheimer and Parkinson diseases. A hallmark of these diseases is the …

Protein misfolding and aggregation are known to play a crucial role in a number of important
human diseases (Alzheimer's, Parkinson's, prion, diabetes, cataracts, etc.) as well as in a …

Aggregation of amyloid β-peptide (Aβ) is implicated in the pathology of Alzheimer's disease
(AD), with the soluble, Aβ oligomeric species thought to be the critical pathological species …

Soluble amyloid β (Aβ) aggregates, suggested to be the most toxic forms of Aβ, draw
attention as therapeutic targets and biomarkers of Alzheimer's disease (AD). As soluble Aβ …

Soluble amyloid β-protein (Aβ) oligomers, the main neurotoxic species, are predominantly
formed from monomers through a fibril-catalyzed secondary nucleation. Herein, we virtually …

Amyloids are proteins of a cross-β structure found as deposits in several diseases and also
in normal tissues (nails, spider net, silk). Aromatic amino acids are frequently found in …

In order to evaluate potential therapeutic targets for treatment of amyloidoses such as
Alzheimer's disease (AD), it is essential to determine the structures of toxic amyloid …